[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solid-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solid-neoplasm":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100332134","phase-1-serial-imaging-of-the-novel-radiotracer-18f-fluorthanatrace-18f-ftt-by-petctf-100332134",false,"NCT03604315","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCTF","Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET\u002FCT","Inclusion Criteria:\n\n* History of known or suspected solid tumor.\n* At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\], ultrasound, fludeoxyglucose \\[FDG\\] PET\u002FCT).\n\nExclusion Criteria:\n\n* Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential \\\u003C 2 weeks prior to screening as standard of care.\n* Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* Any current medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.","FEMALE","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)\u002Fcomputed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET\u002FCT uses a scanner to make detailed, computerized pictures of areas inside the body. PET\u002FCT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.",[26,27,28,29,30,31,32,33],"Breast Carcinoma","Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Solid Neoplasm","RECRUITING","2026-04-10",{"date":37,"type":38},"2026-04-15","ACTUAL",{"date":40,"type":38},"2018-12-18",{"date":42,"type":20},"2027-06-30",{"name":44,"class":45},"M.D. Anderson Cancer Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100287556","uwccc-molecular-tumor-board-registry-100287556","NCT03023202","UWCCC Molecular Tumor Board Registry","UWCCC Precision Medicine Molecular Tumor Board Registry","Inclusion Criteria:\n\n* Clinically suspected or histologically confirmed solid or hematological malignancy\n* Undergoing genetic testing of tumor\n* Ability to understand written informed consent document\n* Willingness to sign written informed consent document\n\nExclusion Criteria:\n\n* Pediatric patients (age\\\u003C18 years) will be excluded due to a lack of expertise on the molecular tumor committee","ALL",{"count":56,"type":20},10000,"OBSERVATIONAL","This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.",[60,33],"Hematologic Neoplasms","2026-04-07",{"date":63,"type":38},"2026-04-13",{"date":65,"type":38},"2016-03-30",{"date":67,"type":20},"2029-03",{"name":69,"class":45},"University of Wisconsin, Madison",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100597416","weight-management-in-obese-cancer-patients-during-curative-active-treatment-100597416","NCT07058207","Weight Management in Obese Cancer Patients During Curative Active Treatment","Weight Management in Obese Cancer Patients During Curative Active Treatment (CANOBESE Study): A Feasibility Study","CANOBESE","Inclusion Criteria:\n\n* Adult (age 18+) with pathologically confirmed malignant solid tumors, stage II-IV, elected for oncological treatment (chemo, radio, or both) with curative intend.\n* Expected oncological treatment time ≥ 3 months.\n* BMI ≥ 30 kg\u002Fm²\n* Resident in the Barcelona area up to the completion of cancer treatment.\n* ECOG Perfomance Status (PS) 0-1\n* Availability of internet access.\n\nExclusion Criteria:\n\n* Patients with melanoma and brain tumours.\n* Surgery as the only treatment.\n* Tumour localizations with high risk of malnutrition (such as head and neck, upper gastrointestinal tract, or pancreatic cancer):\n* Pregnancy or breastfeeding\n* Another active malignancy\n* Current health or medical condition that affects weight status, e.g., untreated hyper- or hypothyroidism,etc\n* Pre-existing medical condition that precludes adherence to unsupervised exercise, e.g., severe orthopedic conditions, scheduled for a hip or knee replacement, bone metastases, paralysis, dementia, untreated stage 3 hypertension, or unstable angina, heart attack, congestive heart failure or conditions that dictated hospitalization or oxygen within 6-months.\n* Unable to read or understand Spanish or Catalan\n* Enrolled in a weight loss program\n* Active suicidal ideation, anorexia, bulimia, binge eating disorder, current substance abuse or dependence (besides nicotine dependence)\n* Use of pacemaker or another electrical implanted device\n* History of bariatric (or LapBand) surgery, or considering or currently on a wait-list for bariatric or LapBand surgery\n* Patients with any concurrent medical or psychological condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.",{"count":79,"type":20},50,[81],"NA","This is a feasibility study intervention to fifty cancer patients with obesity and with newly diagnosed stage II-IV solid tumors undergoing curative treatment recruited at the Catalan Institute of Oncology (ICO) in L'Hospitalet, Spain.\n\nThe investigators hypothesize that weight management during cancer treatment could enhance health outcomes for this population. The feasibility of a multimodal weight loss management program will be assesses, including a personalized hypocaloric and high-protein diet combined with a supervised exercise home-program and behavioural support.",[84,33,85,86],"Obesity","Stage II-IV","Curative Treatment",[84,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102],"Neoplasms","Antineoplasic agents","Chemotherapy","Radiotherapy","Weight Loss","Physical Activity","Feasibility Studies","Patient Compliance","Patient Motivation","Patient Adherence","Patient Dropouts","Treatment-related adverse effects","Biomarkers","nutritional intervention","curative-intent treatment","2025-07-24",{"date":105,"type":38},"2025-07-28",{"date":107,"type":38},"2025-07-22",{"date":109,"type":20},"2027-03",{"name":111,"class":45},"Institut d'Investigació Biomèdica de Bellvitge"]